Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Merck
McKinsey
Mallinckrodt
Express Scripts
Boehringer Ingelheim

Last Updated: October 1, 2022

Details for Patent: 8,871,759


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which drugs does patent 8,871,759 protect, and when does it expire?

Patent 8,871,759 protects ZEPATIER and is included in one NDA.

This patent has fifty-one patent family members in thirty-nine countries.

Summary for Patent: 8,871,759
Title:Inhibitors of hepatitis C virus replication
Abstract: The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. ##STR00001##
Inventor(s): Coburn; Craig A. (Royersford, PA), Ludmerer; Steven W. (North Wales, PA), Liu; Kun (Edison, NJ), Wu; Hao (Shanghai, CN), Soll; Richard (San Diego, CA), Zhong; Bin (Shanghai, CN), Zhu; Jian (Shanghai, CN)
Assignee: Merck Sharp & Dohme Corp. (Rahway, NJ)
Application Number:13/260,684
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 8,871,759

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Msd Sub Merck ZEPATIER elbasvir; grazoprevir TABLET;ORAL 208261-001 Jan 28, 2016 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y TREATMENT OF PATIENTS INFECTED WITH HEPATITIS C VIRUS See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,871,759

PCT Information
PCT FiledMarch 25, 2010PCT Application Number:PCT/US2010/028653
PCT Publication Date:September 30, 2010PCT Publication Number: WO2010/111483

International Family Members for US Patent 8,871,759

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2010229833 See Plans and Pricing
Brazil PI1013394 See Plans and Pricing
Canada 2756172 See Plans and Pricing
China 102427729 See Plans and Pricing
China 103880862 See Plans and Pricing
China 109651342 See Plans and Pricing
Colombia 6420390 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Medtronic
Boehringer Ingelheim
Merck
Baxter
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.